Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07079592
Recruiting Not applicable

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

NCT07079592 · tracked via the Priya Life Science Taiwan tracker
Sponsor
National Defense Medical Center, Taiwan
Phase
Not applicable
Started
2026-02
Last updated
2026-02-24

Condition(s) studied

Artificial Intelligence (AI)Artificial Intelligence (AI) in DiagnosisHypertension, Pulmonary

Investigational drug(s) / intervention(s)

AI-ECG Guidance

AI-ECG Guidance: Participants undergo screening using the AI-ECG system. Those identified as high-risk for pulmonary hypertension receive echocardiography to confirm the diagnosis and guide subsequent management.

Study summary

This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Men or women, ≥ 50 to 85 years of age * At least one 12-lead ECG within 3 months Exclusion Criteria: * A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5 * A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy * Prior heart, lung, or heart-lung transplants * Any systolic pulmonary artery pressure \>50 mmHg by echocardiography before * Echocardiography in 3 months before index ECG

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Defense Medical Center Taipei Taiwan Recruiting

More National Defense Medical Center, Taiwan trials in Taiwan

AI Chatbot-Assisted Aerobic Exercise Guided by the Transtheoretical Model and Self-determination Theory With Machine Learning Algorithms to Provide Real-time, Personalized Feedback in Traumatic Brain Injury Recruiting
Effects of Intelligent Parent-child Bonding Intervention on the Physical, Psychological and Social Health of Parents of Premature Infants During Hospitalization and Return Home Recruiting
The VALVE-AI Trial Recruiting
The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value-Based Payment System Recruiting
Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development Recruiting

Other trials for the same condition

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Active, not recruiting
Barriers and Facilitators to Nursing Record With AI Technology Application Starting soon
The Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value-Based Payment System Recruiting
Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development Recruiting
AI-Assisted Smart Interactive Healthcare Robot Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07079592 on ClinicalTrials.gov ↗ ← All trials in Taiwan